Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival

Oncogene

Volumn 33, Issue 10, 2014, Pages 1336-1339

  Fang, M ^a,b,c   Simeonova, I ^a,b,c   Bardot, B ^a,b,c   Lejour, V ^a,b,c   Jaber, S ^a,b,c   Bouarich Bourimi, R ^a,b,c   Morin, A ^a,b,c   Toledo, F ^a,b,c  

^a INSTITUT CURIE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Institut Curie   (France)

Author keywords

Mdm4; p21; p53; Plk1; Rb

Indexed keywords

PROTEIN MDMX; PROTEIN P53;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; EMBRYO; GENE EXPRESSION; GENE LOSS; GENE REPRESSION; HYPOPHYSIS ADENOMA; MISSENSE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; THYROID CARCINOMA;

ANIMALIA; MUS;

ADENOMA; ANIMALS; HUMANS; MICE; MICE, KNOCKOUT; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS; RETINOBLASTOMA PROTEIN; SURVIVAL ANALYSIS; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84895922081     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.62     Document Type: Article

References (25)

1. Toledo F, Wahl GM. Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6: 909-923
2. Marine JC. MDM2 and MDMX in cancer and development. Curr Top Dev Biol 2011; 94: 45-75
3. Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M et al. A mouse p53 mutant lacking the proline rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 2006; 9: 273-285
4. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444: 61-66
5. Bernal F, Wade M, Godes M, Davis TN, Whitehead DG, Kung AL et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 2010; 18: 411-422
6. Vaseva AV, Yallowitz AR, Marchenko ND, Xu S, Moll UM. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with nutlin to induce p53-mediated apoptosis in solid tumors. Cell Death Dis 2011; 2: E156
7. Garcia D, Warr MR, Martins CP, Brown Swigart L, Passegue' E, Evan GI. Validation of MdmX as a therapeutic target for reactivating p53 in tumors. Genes Dev 2011; 25: 1746-1757
8. Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med 2012; 18: 1239-1247
9. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-629
10. Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G et al. The TP53 website: An integrative resource centre for the TP53 mutation Database and TP53 mutant analysis. Nucleic Acids Res 2012; 41: D962-D969
11. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 1994; 7: 480-484
12. Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S et al. p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci USA 2008; 105: 17498-17503
13. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-684
14. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 2007; 67: 10158-10158
15. Nappi TC, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G, Santoro M. Identification of polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res 2009; 69: 1916-1923
16. McKenzie L, King S, Marcar L, Nicol S, Dias SS, Schumm K et al. p53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle 2010; 9: 4200-4212
17. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848
18. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 1999; 13: 2490-2501
19. Zilfou JT, Hoffman WH, Sank M, George DL, Murphy M. The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasomemediated degradation. Mol Cell Biol 2001; 21: 3974-3985
20. Lohr K, Moritz C, Contente A, Dobbelstein M. p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem 2003; 278: 32507-32516
21. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA et al. Effects of an Rb mutation in the mouse. Nature 1992; 359: 295-300
22. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4: 1-7
23. Prophet E, Mills B, Arrington J, Sobin L. Afip-Laboratory methods in histotechnology. American Registry of Pathology: Washington DC, USA, 1992
24. Simeonova I, Lejour V, Bardot B, Bouarich-Bourimi R, Morin A, Fang M et al. Fuzzy tandem repeats containing p53 response elements may define species-specific p53 target genes. PLoS Genet 2012; 8: E1002731
25. Migliorini D, Lazzerini Denchi E, Danovi D, Jochemsen A, Capillo M, Gobbi A et al. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 2002; 22: 5527-5538